Sponsor: Merck
Sponsor Study ID: MK-3543-006
Study Title: Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia
CTO #: 104108
NCT Number:
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Hematopoietic
Study Objectives: To compare bomedemstat to best available therapy with respect to DCHR. To compare bomedemstat to best available therapy with respect to change in fatigue score based on MFSAF v4.0.